Document is current
Any future updates will be listed below
-
Authors
He, Jun Yan
Kim, Yang-Joon
Mennillo, Elvira
Rusu, Iulia
Bain, Jared
Rao, Arjun A
Andersen, Christopher
Law, Karen
Yang, Hai
Tsui, Jessica
Shen, Alan
Davidson, Brittany
Kushnoor, Divyashree
Shi, Yimin
Fan, Frances
Cheung, Alexander https://orcid.org/0000-0002-2115-6966
Zhang, Li
Fong, Lawrence
Combes, Alexis J
Pisco, Angela O
Kattah, Michael G
Oh, David Y https://orcid.org/0000-0002-3310-0994
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04407247 at ClinicalTrials.govDocuments that mention this clinical trial
Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab
https://doi.org/10.1136/jitc-2021-002742
Acknowledging and addressing real-world challenges to treating immune-related adverse events
https://doi.org/10.1136/jitc-2024-009540
Dysregulation of CD4<sup>+</sup>and CD8<sup>+</sup>resident memory T, myeloid, and stromal cells in steroid-experienced, checkpoint inhibitor colitis
https://doi.org/10.1136/jitc-2023-008628
Managing IBD in patients with previous cancers
https://doi.org/10.1136/flgastro-2022-102187
Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events
https://doi.org/10.1136/jitc-2021-002850
Steroid-sparing strategies for managing immune-related adverse events
https://doi.org/10.1136/jitc-2025-013776
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study
https://doi.org/10.1136/jitc-2021-003277
Randomized clinical trial of infliximab versus vedolizumab for immune checkpoint inhibitor related colitis.
https://doi.org/10.1200/jco.2024.42.16_suppl.2661
-
Funding
Funding for this research was provided by:
National Institutes of Health (K08AI139375)
National Institutes of Health (K08DK123202)
UCSF ImmunoX (CoPilot Award)
Crohn’s and Colitis Foundation (Career Development Award)
Parker Institute for Cancer Immunotherapy (N/A)
V Foundation for Cancer Research (T2023-011)
Burroughs Wellcome Fund (Career Award for Medical Scientists)
Damon Runyon Cancer Research Foundation (CI 110-21)
- License Information
